Table 2.
Number of molnupiravir and nirmatrelvir–ritonavir orders by country, and percentage of fully vaccinated individuals as of Dec 31, 2021
|
Number of treatment courses |
Percentage of the total population who are fully vaccinated* | ||
|---|---|---|---|
| Molnupiravir | Nirmatrelvir–ritonavir | ||
| Australia | 300 000 | 500 000 | 77% |
| Belgium | 10 000 | .. | 76% |
| Canada | 500 000 | 1 000 000 | 77% |
| Germany | .. | 1 000 000† | 71% |
| Indonesia | 600 000–1 000 000 | .. | 41% |
| Israel | .. | 100 000 | 64% |
| Italy | 50 000 | 50 000 | 74% |
| Japan | 1 600 000 | .. | 78% |
| Malaysia | 150 000 | .. | 78% |
| Philippines | 300 000 | .. | 34% |
| South Korea | 200 000 | 70 000 | 83% |
| Switzerland | 8640 | 50 000‡ | 67% |
| Thailand | 200 000 | .. | 65% |
| UK | 2 230 000 | 2 750 000 | 70% |
| USA | 3 100 000 | 10 000 000 | 62% |